Related Experiment Video

Updated: Apr 26, 2026

In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines
08:50

In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines

Published on: April 18, 2025

1.0K

Sox17 inhibits hepatocellular carcinoma progression by downregulation of KIF14 expression

Tao Yang1, Xiao-Na Li, Li Li

  • 1Department of Hepatobiliary Surgery, The First Hospital of Shijiazhuang City, Shijiazhuang, China.

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|August 10, 2014
PubMed

Insights

Sox17, a Wnt/β-catenin signaling antagonist, is downregulated in hepatocellular carcinoma (HCC). Sox17 inhibits HCC progression by reducing KIF14 expression, offering a potential therapeutic strategy for liver cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Hepatology

Background:

  • Sox17 antagonizes Wnt/β-catenin signaling, impacting carcinogenesis.
  • Its role in hepatocellular carcinoma (HCC) remains largely unexplored.
  • KIF14 is recognized as an oncogene in various cancers, including HCC.

Purpose of the Study:

  • To investigate the role and mechanism of Sox17 in hepatocellular carcinoma (HCC).
  • To determine the relationship between Sox17 and KIF14 expression in HCC.
  • To explore Sox17 as a potential therapeutic target for HCC.

Main Methods:

  • Analysis of Sox17 expression in HCC tissues.
  • Assessment of Sox17's effects on HCC cell proliferation and migration.
  • Investigation of the regulatory relationship between Sox17 and KIF14.
  • Evaluation of KIF14's role in Sox17-mediated HCC inhibition.

Main Results:

  • Sox17 expression is significantly downregulated in HCC tissues.
  • Sox17 overexpression suppresses HCC cell proliferation and migration.
  • Sox17 expression is inversely correlated with KIF14 expression in HCC.
  • Sox17 inhibits HCC progression through transcriptional downregulation of KIF14.

Conclusions:

  • Sox17 acts as a tumor suppressor in HCC.
  • The Sox17/KIF14 axis represents a novel mechanism in HCC development.
  • Targeting Sox17 may offer a promising therapeutic strategy for HCC treatment.

More Related Videos

Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma07:47

Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma

Published on: August 31, 2022

2.2K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Pleiotropy01:33

Pleiotropy

Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
31.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K